High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

BACKGROUND: The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended in international guidelines. In these cases,...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Hanne, Mortz, Charlotte G., Bindslev‐Jensen, Carsten, Reilev, Mette, Hallas, Jesper, Henriksen, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665689/
https://www.ncbi.nlm.nih.gov/pubmed/34938439
http://dx.doi.org/10.1002/clt2.12085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665689/
https://www.ncbi.nlm.nih.gov/pubmed/34938439
http://dx.doi.org/10.1002/clt2.12085

Ejemplares similares